Trials / Recruiting
RecruitingNCT06768528
Association Between GalectiN-3 and POSt-operative AtrIal Fibrillation After Coronary Artery BypaSs Graft
Association Between Galectin-3 and Post-operative AtrIal Fibrillation After Coronary Artery Bypass Graft
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 90 (estimated)
- Sponsor
- University of Sao Paulo General Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this observational study is to test the association between high levels of Galectin-3 and the occurrence of post-operative atrial fibrillation after isolated coronary artery bypass grafting (CABG). The main question\[s\] it aims to answer are: * Is Galectin-3 an accurate biomarker to predict higher risk of developing post-operative atrial fibrillation? * Are high levels of Galectin-3 associated to other post-operative complications and major adverse cardiovascular events? Participants will be enrolled during pre-operative evaluation and a peripheral blood sample collection will be performed in the 24h before CABG. Participants will then be followed for a period of 12 months (daily during hospitalization and 3 appointments after hospital discharge) to determine whether patients with higher levels of Galectin-3 will have worse outcomes.
Detailed description
Prospective, observational, single-center cohort study including patients undergoing coronary artery bypass graft (CABG) surgery. Patients will be enrolled during preoperative evaluation. A peripheral blood sample will be collected within 24 hours before surgery and patients will be followed during hospitalization and for 12 months after discharge.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Galectin-3 dosage | Peripheral blood sample will be collected in the 24h before CABG |
Timeline
- Start date
- 2023-01-01
- Primary completion
- 2025-02-28
- Completion
- 2026-12-01
- First posted
- 2025-01-10
- Last updated
- 2025-01-10
Locations
1 site across 1 country: Brazil
Source: ClinicalTrials.gov record NCT06768528. Inclusion in this directory is not an endorsement.